REG - IQ-AI Limited - IB & GE HealthCare Enter into Commercial Agreement

IQ-AIAnnouncement

18/08/2023 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230818:nRSR8077Ja&default-theme=true

RNS Number : 8077J  IQ-AI Limited  18 August 2023

18 August 2023

IQ-AI Ltd

("IQ-AI" or the "Company")

 

IB and GE HealthCare Enter into Commercial Agreement

 

IB Neuro and IB Delta T1 to be embedded in GE HealthCare's (GEHC) MR Smart
Subscription

 

Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE:
IQAI, OTCQB: IQAIF), is pleased to announce that it has entered into a
commercial agreement with GE HealthCare ('GEHC'). The agreement makes IB's
products available on GEHC's MR Smart Subscription.

 

IB Neuro and IB Delta T1 maps are applications that accept magnetic resonance
imaging (MRI) data as input and automatically compute quantitative and
proprietary images as output.

 

The global MRI market is projected to grow at a rate of 7% and surpass $11
billion by 2030, and GEHC is a leading player in that market. A factor driving
that growth are complementary advancements in imaging software, such as IB's
quantitative solutions.  1 

 

The agreement will make IB's solutions available directly to the large number
of sites with GEHC systems already installed as well as new systems scheduled
for installation. Ultimately, this agreement streamlines clinical adoption of
IB's solutions and represents a potential transformational step-change in
business activity for IQAI.

 

"This agreement with GEHC is a major development for IQAI," said Trevor Brown,
CEO of IQ-AI. "It means that any hospital or imaging center that has a GEHC
MRI scanner and MR Smart Subscription will have access to IB's solutions."

 

1.    Magnetic Resonance Imaging Equipment Market Forecast, 2030
(fortunebusinessinsights.com)
(https://www.fortunebusinessinsights.com/industry-reports/magnetic-resonance-imaging-mri-equipment-market-100087)

 

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

For further information, please contact:

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

About Imaging Biometrics® LLC:  IB is a wholly-owned subsidiary of IQ-AI
Limited, (LON: IQAI) (OTCQB: IQAIF), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
Imaging Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on Twitter, @IQAI_IB.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFAFSAEDSEFA